Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for neurodegenerative diseases and endocrine disorders in the United States. Its pipeline includes avexitide, an investigational GLP-1 receptor antagonist being studied in phase 3 trials for post-bariatric hypoglycemia and congenital hyperinsulinism. The company is also advancing AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol, in phase 2 development for wolfram syndrome and in phase 2b/3 testing for progressive supranuclear palsy. Additional programs include AMX0114 for amyotrophic lateral sclerosis, along with longer-acting and other GLP-1 receptor antagonist candidates aimed at post-bariatric hypoglycemia and rare diseases. Founded in 2013, Amylyx is headquartered in Cambridge, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-AMLX
|
$14
|
-23.3% Downside
|
Overvalued
|
$24.70
|
35.3% Upside
|
Undervalued
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 6, 2026
|
-13.6x
|
7.5x
|
—
|
1.94 B
|
1.761 B
|
0.3%
|
75.1%
|
52.5
|
—
|
80.3%
|
